Regeneron Shares Jump As Eye Drug Meets New Study Goal
June 06, 2013 at 15:52 PM EDT
Regeneron Pharmaceuticals (REGN) has been one of the biotechnology industry’s most successful stocks over the last two years. And today, the shares are up almost 9%, or $20.65 to $250 after its eye medication Eylea was shown to improve the vision of patients suffering from myopic choroidal neovascularization (also called mCNV). Late-stage clinical trial data released [...]
